CRISPR Therapeutics (NASDAQ: CRSP) said sales of Casgevy, the sickle cell and beta thalassemia therapy it shares with Vertex Pharmaceuticals (NASDAQ: VRTX), reached $99 million in the third quarter. Shares fell about 2% in early after-hours trading. Casgevy is starting to pay CRISPR back, but the quarterly loss barely moved, so the pipeline still carries the stock.
POLARIS INSIGHTS